HC Wainwright & Co. Maintains Buy on Upstream Bio, Lowers Price Target to $18
Upstream Bio, Inc. (UPB) Reports Q3 Loss, Lags Revenue Estimates
Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress
Upstream Bio Q3 EPS $(0.75) Misses $(0.72) Estimate, Sales $395.000K Miss $480.143K Estimate
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
HC Wainwright & Co. Reiterates Buy on Upstream Bio, Maintains $36 Price Target
Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027
JP Morgan Maintains Neutral on Upstream Bio, Raises Price Target to $9
Truist Securities Maintains Buy on Upstream Bio, Lowers Price Target to $25
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
Upstream Bio Q2 EPS $(0.73) Beats $(0.76) Estimate, Sales $773.000K Beat $430.714K Estimate
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?
Reported Sunday, Upstream Bio Presents Phase 2 VIBRANT Data Showing 79% Of Verekitug-Treated CRSwNP Patients Achieved Clinically Meaningful Nasal Polyp Score Improvements Versus 24% On Placebo
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
JP Morgan Downgrades Upstream Bio to Neutral, Lowers Price Target to $8
Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
Upstream Bio to Present New Verekitug Data at EAACI 2026, Phase 2 Nasal Polyps Analysis Gets EAACI Oral Presentation
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.